English
Find a Study Now
Welcome to the future of
clinical research recruitment

Receive The Newest Study Notifications

Select Page

FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer

FibroGen, Inc., (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC). “Patients with unresectable locally advanced pancreatic cancer...
SEARCH FOR STUDIES